TrialSignal
Clinical trial intelligence report
Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT01484262-Jul 28, 2026
NCT ID
NCT01484262
Status
COMPLETED
Phase
registry-stage
Sponsor
Novo Nordisk A/S
Executive brief
Investment-Ready Snapshot
Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2 is a registry-stage clinical asset sponsored by Novo Nordisk A/S in Diabetes, Diabetes Mellitus, Type 2. SEO and diligence focus: liraglutide, insulin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01484262
Indication
Diabetes
Modality
small molecule
Target
liraglutide, insulin
Intervention
liraglutide, insulin
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.